Federal Register #E0282023

NIH Seeks Partners for PEDF Peptide Retinal Therapy and VSVBDBV Vaccine Licensing

This opportunity from the National Institutes of Health (NIH) seeks partners for licensing and co-development of two innovative, government-owned biomedical inventions: - Government Buyer: - Department of Health and Human Services (HHS) - National Institutes of Health (NIH) - National Eye Institute (NEI) - National Institute of Allergy and Infectious Diseases (NIAID) - OEMs/Inventors: - National Eye Institute (NEI) - National Institute of Allergy and Infectious Diseases (NIAID) - Products/Technologies Requested: - PEDF 17-mer [H105A] Peptide Therapy (Part Number: E0282023) - Gene-agnostic peptide for inherited retinal diseases and age-related macular degeneration - Delivery via eyedrop formulation or AAV2 vector - Neurotrophic and antiangiogenic properties - Replication-Competent rVSVBDBV Vaccine (Part Number: E12220260) - Vaccine for rapid prevention and post-exposure protection against Bundibugyo virus (BDBV) - Utilizes vesicular stomatitis virus (VSV) vector expressing BDBV glycoprotein - Related to the rVSV platform used in the licensed Ebola vaccine Ervebo - Unique/Notable Requirements: - Both inventions are at the pre-clinical stage and available for licensing or collaborative research - PEDF peptide therapy is mutation-independent (gene-agnostic), suitable for a broad range of inherited retinal diseases - VSVBDBV vaccine is designed for rapid, single-dose protection, including post-exposure scenarios - Seeking commercial partners for further development, evaluation, and commercialization

Description

The National Eye Institute (NEI) is seeking research co-development partners and/or licensees to develop an AAV2-based delivery system or an eyedrop formulation to deliver a Pigment Epithelium-Derived Factor (PEDF) peptide. This gene-agnostic approach aims to treat inherited retinal diseases such as retinitis pigmentosa and age-related macular degeneration. The technology includes a proprietary 17-mer PEDF peptide with neurotrophic and antiangiogenic properties, designed to protect photoreceptors and prevent vision loss. The invention is available for licensing and co-development to advance treatment options for retinal degenerations.

View original listing